GlassScriptPhysician profile
Purnima S Patel
NPI 1316124183
$15,630.73
in general payments reported to CMS, 2019-2025
32 companies · $5,028 in 2025
The $5,028 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $246 · 2021: $492 · 2022: $2,036 · 2023: $1,881 · 2024: $5,531 · 2025: $5,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,698 · Consulting Fee: $5,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,698.03 |
| Consulting Fee | $5,742.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $3,739.38 | 2022-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Genentech USA, INC. | $1,890.93 | 2021-2025 | Vabysmo |
| Alcon Vision LLC | $1,874.33 | 2019-2025 | Clareon, Unity, Hydrus Microstent |
| Lensar, INC. | $1,300.00 | 2025 | Lensar Laser System |
| Bausch & Lomb Americas INC. | $1,181.83 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Abbvie INC. | $957.65 | 2022-2025 | |
| Eyepoint US, INC. | $755.25 | 2019-2023 | |
| Harrow Eye, LLC | $541.80 | 2024-2025 | Vevye, Triesence, Iheezo |
| Regeneron Healthcare Solutions, INC. | $424.02 | 2020-2025 | Eylea Hd, Eylea |
| Tarsus Pharmaceuticals, INC. | $360.35 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $226.74 | 2023-2025 | Syfovre |
| Rxsight INC | $218.18 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Astellas Pharma US INC | $214.94 | 2023-2025 | Izervay |
| Sight Sciences, INC. | $199.59 | 2022-2024 | Tearcare System |
| Alimera Sciences, INC. | $195.27 | 2021-2024 | Iluvien, Yutiq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $191.63 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $171.00 | 2024-2025 | Humphrey Hfa |
| Allergan, INC. | $161.09 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $146.10 | 2021 | |
| Coherus Oncology, INC. | $138.04 | 2022-2024 | |
| Dompe US, INC. | $128.80 | 2022-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $112.87 | 2024 | Catalys System, Veritas Vision System |
| Biotissue Holdings INC. | $96.18 | 2023-2024 | |
| Notal Vision, INC. | $76.56 | 2022 | |
| Lombart Brothers, INC. | $68.81 | 2022-2025 | Opd-III |
| Ani Pharmaceuticals, INC. | $51.54 | 2025 | Iluvien |
| Biogen, INC. | $49.43 | 2023 | |
| Sandoz INC. | $49.29 | 2024 | Cimerli |
| Mallinckrodt Hospital Products INC. | $29.96 | 2022 | |
| Rayner Intraocular Lenses Limited | $28.42 | 2024 | Omidria, Rayone Spheric, Rayone Emv |
| Tearlab Corp | $26.93 | 2024 | Scoutpro Osmolarity System |
| Oyster Point Pharma, INC. | $23.82 | 2024 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purnima Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.